Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Maxygen,'s share price for the quarter that ended in Mar. 2013 was €1.826. Maxygen,'s Shares Outstanding (EOP) for the quarter that ended in Mar. 2013 was 27.52 Mil. Therefore, Maxygen,'s market cap for the quarter that ended in Mar. 2013 was €50.25 Mil.
Maxygen,'s quarterly market cap
declined
from Sep. 2012 (€57.48 Mil) to Dec. 2012 (€54.17 Mil) and
declined
from Dec. 2012 (€54.17 Mil) to Mar. 2013 (€50.25 Mil).
Maxygen,'s annual market cap
declined
from Dec. 2010 (€87.37 Mil) to Dec. 2011 (€0.00 Mil) but then
increased
from Dec. 2011 (€0.00 Mil) to Dec. 2012 (€54.15 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Maxygen,'s Enterprise Value for Today is €52.99 Mil.
Maxygen, Market Cap Historical Data
The historical data trend for Maxygen,'s Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Maxygen,'s Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Maxygen,'s Market Cap Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Maxygen,'s Market Cap distribution charts can be found below:
* The bar in red indicates where Maxygen,'s Market Cap falls into.
Maxygen, Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Maxygen,'s Market Cap for the fiscal year that ended in Dec. 2012 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Maxygen, (FRA:MYN) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Maxygen, Market Cap Related Terms
Thank you for viewing the detailed overview of Maxygen,'s Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Maxygen, Inc., is incorporated in Delaware. It is a biotechnology company. It discovers and develops improved next-generation protein pharmaceuticals for the treatment of disease and serious medical conditions. The Company's MAXY-G34 product candidate has been designed to be an improved next-generation pegylated, G-CSF for the treatment of chemotherapy-induced neutropenia. G-CSF is a natural protein that functions by stimulating the body's bone marrow to produce more white blood cells. The Company completed a Phase IIa clinical trial for its MAXY-G34 product candidate for the treatment of chemotherapy-induced neutropenia in breast cancer patients in which MAXY-G34 was safe and effective in reducing chemotherapy-induced neutropenia with no serious adverse events, drug-related grade 3 or 4 adverse events or immunogenicity reported in any patient receiving MAXY-G34. Adverse events were consistent with known side effects of G-CSF molecules. The Company is subject to regulation by the FDA and comparable regulatory agencies in foreign countries with respect to any development and commercialization of its MAXY-G34 product candidate or any other products it may acquire in the future.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:MYN has been successfully added to your 